Recently, optogenetic techniques have emerged as a method to optically manipulate molecular and cellular events in target cells both in vitro and in vivo. Optogenetics results from the fruitful combination of optics and genetic engineering, maximizing the advantages of each discipline. These advantages are optical control through the manipulation of wavelength and light intensity on the millisecond timescale, and specific gene expression and gene product trafficking with subcellular precision. This kind of fine-tuning cannot be achieved using traditional methods. Therefore, optogenetic techniques have brought a revolution to neuroscience. In this review, we provide a concise summary of the history and recent advances of optogenetics, focusing in particular on applications for psychiatric research.
BACKGROUND OF OPTOGENETICS
Optogenetics uses a combination of genetic and optical methods to control the cellular events in specific cells of living tissue. Opsins, lightsensitive photoreceptor molecules of the visual system across the animal kingdom, are a crucial tool for optogenetics. Among the opsin family, microbial opsins (bacteriorhodopsins, halorhodopsins [HR] , and channelrhodopsins [ChR] ) are of particular interest because of their advantageous gene structure, encoding both light sensing and the effector domains (Fig. 1a) . Therefore, microbial opsins can induce light sensitivity to biologically well-tolerated wavelengths and intensities into non-light-sensitive cells. The resulting ion flux triggers cellular events, such as an action potential -an electrical signal that propagates along the axon. The ability to optically control action potential generation and firing has attracted considerable attention in the field of neuroscience. The greatest advantage of this novel technique lies in the ability to modulate neuronal function in a spatiotemporally precise manner by exploiting genetic engineering methods. Genetic engineering methods enable the expression of opsins in specific neuronal populations and/or desired subcellular locations. Furthermore, because of the ability to precisely control the width, frequency, and latency of the optical pulse on the millisecond timescale, optogenetics can be applied to investigate the neuronal coding underlying behaviors in vivo. The same degree of control cannot be achieved when using traditional methods, such as direct stimulation with electrodes. Stimulation with electrodes activates different neuronal subtypes located within the electrical field, resulting in low spatial resolution (Fig. 1b) . In this respect, optogenetics provides a greater degree of experimental versatility and precision.
THE HISTORY AND REPERTOIRE OF OPTOGENETICS TOOLS
Almost half a century ago, bacteriologists discovered that some bacteria contain proteins that directly regulate ion flow across the plasma membrane in response to light. Bacteriorhodopsin was identified in 1971 as functioning as a proton pump activated by green light. 1 Successfully applied, opsins should have a marked impact on neuroscience. Using lightinduced ion flux, neuroscientists can control the membrane potential of targeted neurons. This technique opens a completely new approach to investigating how neuronal networks work, and how they relate to behavioral responses. Simultaneously, the optogenetic techniques can provide important information about coding and computation in neural circuits. However, this application of opsins was thought unlikely to be successful because opsin-induced photocurrents were assumed to be too slow and weak to elicit an action potential in mammalian neurons. In 2005, a seminal work from Karl Deisseroth's lab demonstrated that the channel conductance of channelrhodopsin-2 (ChR2) was sufficient to drive mammalian neurons above the ChR2 is a cation channel that opens in response to blue light, triggering a large influx of Na + and Ca
2+
. This inward Na + current causes a rapid depolarization of the cell membrane and, consequently, neuronal firing. An example of current-clamp recordings showing firing of a single neuron in response to sustained and pulsed blue light. NpHR is a chloride pump that is activated by yellow light, resulting in a strong hyperpolarization of the membrane and, consequently, inhibition of neuronal firing. [DTE]), which allow AS-PaRac1 to specifically localize in the potentiated spines. Upon blue-light radiation, the light-oxygenvoltage (LOV)2 domain of PaRac1 unfolds, triggering downstream signaling of Rac1 and resulting in the shrinkage of the potentiated spine. (d) Molecular structure of Gal4-VVD-p65 optimized transcription factor (GAVPO). Upon blue-light radiation, the LOV domain rapidly induces dimerization of GAVPO, triggering the transcription of specific genes containing Gal4-binding sites in their promoter region. SARE, synaptic activity-responsive element; UAS, upstream activating sequence.
action potential threshold. Consequently, neural activity can be controlled by blue light with millisecond temporal precision (Fig. 1a) . 2 Since this success, additional variants of the ChR2 families have been engineered to achieve faster kinetics. For example, mutating the E123 residue accelerates channel kinetics (ChR2/E123T, known as ChETA), allowing sustained spike trains up to at least 200 Hz. 3 Furthermore, ChIEF (chimera EF with I170V mutation), another variant of ChR, has been developed by creating chimeric ChR from ChR1 and ChR2 combined with site-directed mutagenesis. 4 ChIEF shows the largest photocurrents, reduced inactivation during persistent light stimulation, and improved fidelity at frequencies higher than 25 Hz, thereby allowing the induction of spike trains that more closely resemble natural fast spiking patterns. Although millisecond scale temporal control is one of the major strengths of ChR variants, a C128S mutation and C128S/D156A double mutations of ChR2 generated step-function opsins (SFO) and stabilized SFO, respectively. These SFO show an extended lifetime of the channel open state, enhanced kinetic stability, and bi-stable currents. These factors enable a stable photocurrent for a longer duration before deactivation via illumination at another wavelength. 5, 6 The long and stable photocurrent induced by stabilized SFO allows these opsins to potentially manipulate the balance between excitation and inhibition (cellular E/I balance) over 30 min and for the behavioral output in freely moving mice to be observed. 6 The blue-light-gated cation channel ChR2 and its variants are potent tools for optogenetics. However, enormous efforts have been focused on developing additional tools. In particular, researchers have been developing another cation channel with an activation spectrum that is substantially red-shifted relative to ChR2 in order to visualize interactions of distinct neuronal circuits. Utilizing the genome database, a previously unknown microbial ChR with peak response at around 530 nm has been discovered from Volvox carteri (VChR1). 7 Due to several limitations of initial VChR1, such as slow channel kinetics, poor membrane trafficking, and incomplete recovery from the desensitized state, newer redshifted ChR variants require intensive improvement. Successful gene-engineering strategies, such as sequence replacement and mutagenesis, used for the engineering of ChIEF, have been applied to VChR1 resulting in the optimization of a new variant red-activatable ChR (ReaChR). ReaChR is optimally excited by red light (wavelength 590-630 nm). In addition, ReaChR offers improved membrane trafficking, higher photocurrents, and faster kinetics compared with VChR1. 8 Thus, ReaChR could be used together with conventional ChR for labeling distinct cell types, allowing for the optical control of the respective cell types. Furthermore, ReaChR also offer a substantial advantage in terms of neuronal stimulation of deeper brain regions, because red light is less scattered by tissue and is less absorbed by blood compared to light of shorter wavelengths used to excite classic ChR variants. Rayleigh scattering is one main cause of optical loss by optical fibers. The scattering is inversely proportional to the fourth power of the wavelength of light. Consequently, blue light (shorter wavelength of 473 nm) is scattered three times stronger than red light (longer wavelength of 617 nm). Indeed, the first report of ReaChR application elegantly showed that transcranial stimulation of ReaChR in the vibrissal motor cortex elicited vibrissae movements in awake mice. 8 This non-invasive transcranial stimulation method is highly beneficial for chronic studies, because as part of the inflammatory response to cranial window surgery, microglia and astrocytes are activated. Therefore, optogenetic approaches using red-shifted ChR could substantially reduce the invasiveness of therapeutic interventions.
Optogenetics can be used not only to achieve excitation, but also to achieve inhibition of the target neuron. HR from Natronomonas pharaonic (NpHR) is a light-driven chloride pump, pumping chloride anions into the cell. NpHR-expressing neurons exhibit light-evoked hyperpolarization, resulting in inhibition of neuronal firing (Fig. 1a) . 9, 10 NpHR is optimally excited near 580 nm, which is red-shifted compared to ChR2 (maximum at around 460 nm). Thus, ChR2 and NpHR could be activated independently or in synchrony. Indeed, in their original work on NpHR, Zhang et al. showed that it is possible to simultaneously express NpHR and ChR2 in cholinergic motor neurons of Caenorhabditis elegans to control locomotion bidirectionally. 9 The possibility to separately control excitatory and inhibitory neurons rendered it possible to directly and causally link specific neuronal circuits to related behavioral manifestations. More recently, additional photoinhibitory membrane proteins have been discovered from Halorubrum sodomense (archaerhodopsin-3, also known as Arch) and Leptosphaeria maculans (known as Mac), a green-yellow light-driven outward proton pump and a blue-green light outward proton pump, respectively. 11 When expressed in neurons, Arch mediates rapid and reversible silencing of neural activity by pumping protons out of the cell, thereby hyperpolarizing it. The photocurrent induced by Arch activation is larger than the photocurrent induced by NpHR and can induce nearly complete silencing of neural activity in awake-behaving mice. 11 Another type of optogenetic inhibitory tool is the anion ChR (ACR) -a family of light-gated anion channels expressed in cryptophyte algae. ACR are the most light-sensitive among the currently available optogenetic inhibitors with anion selectivity and rapid kinetics. 12 This increasing variety of light absorption spectra among the different types of inhibitory optoprobes potentially allows us to independently silence distinct neural populations by using different light wavelengths. Moreover, these optoprobes and their variants are being assiduously improved and new variants are being invented to create optoprobes with different pump/channel kinetics, ion conductance, and light absorption properties. Finally, multiple-color optical activation, silencing, and (de)synchronization of neuronal activity should allow us to causally dissect how specific elements of neuronal circuits contribute to neuronal coding and related behaviors.
Although optogenetic techniques generally work beautifully in small rodents, several technical improvements (especially a decrease in invasiveness) need to be achieved before these techniques can be translated to larger and more complex animal models. High expression levels of hydrophobic heterologous proteins, such as microbial opsins, can be toxic and alter the intrinsic properties of the plasma membrane. Thus, further optimization of opsins to minimize toxic effects, improve membrane trafficking, and achieve faster kinetics and higher photocurrents is necessary. Most importantly, a decrease in the invasiveness is crucial. Currently light is delivered into the brain via a surgically implanted optical fiber. This technique poses the risk of chronic injection and tissue damage. In addition, transmission of external light through the brain is inefficient due to light scattering and tissue absorption effects; the blue laser beam (480 nm) is attenuated by 50% at 200-μm depth, and by 90% at 1-mm depth from the cerebral cortex. To bypass the challenges of external light delivery, wireless implants with a remote control system are now being developed. One research direction of this kind is up-conversion optogenetics. Lanthanide nanoparticles absorb lowenergy, near-infrared photons to emit high-energy photons of visible light with a peak at 543 nm (upconversion). Because near-infrared photons have been reported as penetrating through skin and bone deep into the brain, Lanthanide nanoparticles can be used to emit visible light that activates ChR to elicit photocurrents in the cells. 13 14 and inhibitory LMO, 15 respectively. Luciferase can act as a light-generating protein for opsins. Ionic currents can be elicited after luciferase activation by coelenterazine administration. LMO and inhibitory LMO can excite or silence neural activity in response to coelenterazine, enabling readily scalable, less invasive, and hardware-independent optogenetic methods. LMO use a diffusible external molecule to control neuronal firing, similar to conventional chemogenetic probes, such as designer receptors exclusively activated by designer drug (DREADD). Temporal control of neuronal firing is dependent on how fast the chemical can reach the brain and is subsequently discharged from the brain. The onset of LMO effects in vivo has been reported from one to several minutes after the chemical injection and the effect has been reported to last several minutes to over 30 min. Thus, kinetics of LMO are faster than kinetics of DREADD (20 min to several hours of action). Moreover, the LMO approach is simpler, because LMO directly generate electrical currents. In contrast, DREADD, which are based on G proteincoupled receptors, require intracellular second messenger pathways that might elicit unexpected off-target effects. Thus, LMO provide a unique approach that combines the advantages of optogenetics (robust control of neuronal firing) with the advantages of the DREADD (non-invasive and broad activation) into a single molecule.
The optoprobes discussed above regulate neuronal firing by modulating neuronal membrane potential via the flow of ions across the cell membrane. Other optogenetic tools have been developed to influence neuronal function via different avenues. For example, photoactivated adenylyl cyclase (Pac), isolated from Euglena gracilis, is a unique protein that functions not only as a photoreceptor, but also as an effector catalyzing cAMP synthesis. Stimulation with blue light causes a rapid increase in cAMP levels 16 and modulation of neurotransmitter release by directly affecting intracellular signaling. Lightsensing domains, such as the light-oxygen-voltage (LOV) domain of phototropin from Avena sativa, offer a novel platform for the construction of optogenetic tools. 17 The LOV2 domain consists of a flavin-binding core domain and the Jα-helical extension at the carboxy-terminus. The LOV2 domain interacts with the Jα-helix in the dark. Upon irradiation with blue light, the core domain forms a covalent adduct with the excited flavin mononucleotide, resulting in a conformational change within the core followed by dissociation and unfolding of the Jα helix. 18 One of the successful applications of the LOV2 domain is photoactivatable Rac1 (PaRac1), in which the LOV2 domain is fused with Rac1 (Fig. 1c) . 19 The LOV domain in its closed conformation blocks the binding of Rac1 to its effector molecules. Light-induced unwinding of the Jα helix from the LOV domain releases steric inhibition, triggering Rac1 signaling. Rac1 is highly enriched in dendritic spines. In dendritic spines, Rac1 regulates the spine size via rearrangement of actin cytoskeleton. [20] [21] [22] The majority of excitatory synapses in the neocortex is formed on the spine, and the structural plasticity of the spine is tightly linked to synaptic function. Thus, optical control of PaRac1 could allow the control of synaptic transmission via structural plasticity. Indeed, optical activation of potentiated spinespecific PaRac1 (AS-PaRac1) in learning-related spines successfully induced shrinkage of those spines, resulting in the deterioration of the acquired learning. 23 This synaptic optogenetics is the first proof of concept demonstrating that the structural plasticity of dendritic spines is the underlying mechanism of learning and memory. Multiple lines of evidence have strongly suggested that the dysregulation of synaptic plasticity underlies a variety of psychiatric disorders, such as schizophrenia, autism, depression, and post-traumatic disorders. 24, 25 Thus, visualization and manipulation of possible synaptic pathology using AS-PaRac1 in validated disease animal models could provide mechanistic insight with synaptic resolution. Likewise, the LOV domain has been used extensively to control protein activity and protein/protein interaction. 26 For example, Wang et al. have utilized the LOV domain to engineer a light-switchable transcription factor, Gal4-VVD-p65 optimized transcription factor (GAVPO). 27 Upon blue-light radiation, the LOV domain rapidly induces dimerization of the well-characterized DNAbinding domain of GAVPO, triggering the transcription of specific genes containing Gal4-binding sites in their promoter regions (Fig. 1d) . GAVPO was kept in the activated state with a half-life of 2 h, allowing optical spatiotemporal control of the gene of interest. In this manner, in principle, any cytosolic protein can be fused to the C-terminus of the Jα helix. After optimization of the linker sequence between Jα helix and the protein of interest, a vast array of photoactivatable forms of enzymes, inhibitory peptides, and DNA-binding proteins could be created using this strategy. Recent advances in psychiatric genetics have shown how disease-associated variations in genes increase disease risk. 24, 25 However, the underlying molecular and cellular mechanisms through which the genetic variations affect brain function cannot be uncovered by genetic studies alone. Spatiotemporal control of the gene of interest using optogenetic tools, such as LOV domains, could provide a new way to examine the causal role of each candidate gene and the possible relation to psychiatric manifestations.
EXAMPLE OF OPTOGENETICS FOR PSYCHIATRIC RESEARCH
The innovative application of opsin proteins for optogenetics has revolutionized many fields of biomedical research, including neuroscience. Therefore, it is not surprising that this technique was selected as the 'Method of the Year' in 2010 by Nature Methods. 28 Furthermore, high-titer adeno-associated viruses carrying double-floxed inverted orientationopsin, empowered by the diverse repertoire of specific transgenic Cre mouse lines, provide a simple but powerful method for opsin delivery into specific cell types of the brain in vivo. This novel strategy allows us to elucidate the role of defined cell types and has been applied to acquire insights into a broad range of scientific questions regarding the behavior, physiology, and pathology in awake animals. In the following sections, we focus on the studies aimed at understanding the neural circuits underlying complex behaviors that are relevant to neuropsychiatric diseases. Because a comprehensive review of all the diverse studies of this kind is beyond the scope of this paper, we restrict ourselves to summarizing three specific categories: (i) investigations of physiological function of neuronal circuits; (ii) deciphering of dysfunctional neuronal circuits as a pathophysiology of psychiatric disorders; and (iii) intervention to normalize altered neuronal function as a possible therapeutic perspective.
Investigations of physiological function of neuronal circuits
The first in vivo optogenetic paper, published in 2007, investigated the role of orexin-producing neurons in awakening from sleep. 29 Because loss of orexin function has been associated with narcolepsy, orexin neurons in the hypothalamus are thought to be important for arousal. 30, 31 However, whether firing of orexin neurons is sufficient for -or simply correlates with -arousal remains unknown. Luis de Lecea's lab used an optical fiber to deliver pulsed blue light to ChR2-expressing orexin neurons of sleeping mice and successfully woke them up, demonstrating the mechanistic and causal contribution of orexin neurons to the sleep-to-wake transition (Fig. 2a) . 29 After this application, neuroscientists actively applied optogenetics in in vivo studies. For example, synchronized firing of © 2017 The Authors Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology fast-spiking parvalbumin interneurons (PV neurons) has long been proposed to underlie gamma oscillations. Because the expression level of PV mRNA is reduced in the layers 3-4 of the dorsolateral prefrontal cortex of subjects with schizophrenia, 32 the PV neuron-related abnormalities in gamma oscillations have been proposed to account for the altered information processing associated with schizophrenia. 33 Until recently, the lack of tools to selectively manipulate PV neurons has hindered the testing of this hypothesis. The emergence of optogenetics has facilitated the control of PV neuron activity on the millisecond timescale. Using this technique, scientists have demonstrated that the inhibition or activation of PV neurons suppressed or drove gamma oscillations, respectively, in vivo. Importantly, optogenetic modification of gamma oscillation has been found to enhance cortical circuit performance by reducing circuit noise.
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Deciphering of dysfunctional neuronal circuits as a pathophysiology of psychiatric disorders
Successful applications of optogenetics have been naturally extended into psychiatric research, such as research on depression, anxiety, and behaviors like reward and motivation in laboratory animals. For example, the use of optogenetics has elegantly demonstrated the significant role of cholinergic interneurons of the nucleus accumbens in cocaine conditioning, 36 midbrain dopamine neurons in depression-like phenotypes induced by chronic mild stress, 37 cortico-striatal projections in obsessivecompulsive behavior mechanisms (Fig. 2b) , 38 and projections from medial prefrontal cortex to basomedial amygdala in the top-down control of anxiety. 39 The unique ability of SFO to alter cellular E/I balance could also lead to significant new findings. For example, multiple lines of evidence have pointed to E/I imbalance as a shared pathophysiological mechanism of autism spectrum disorders. Thus, optogenetically regulating the E/I balance during autism-related behaviors in freely moving mice presented a straightforward experiment. Indeed, an increase in the E/I balance in the medial prefrontal cortex led to specific behavioral impairments, whereas compensatory elevation of inhibitory cell excitability partially rescued the social deficits caused by E/I balance elevation. These results support the causal involvement of an altered E/I balance in the pathophysiology of autistic behaviors. 6 
Intervention to normalize altered neuronal function as a possible therapeutic perspective
Optogenetics also opens new directions for therapy. In a rodent chronic stress model of depression, optical reactivation of hippocampal neurons associated with reward experience resulted in the rescue of stress-induced depression-like behaviors. 40 Interestingly, unlike the optical activation of the reward-related neurocircuits, natural exposure to a rewarding experience did not ameliorate depressionlike behaviors. The ineffectiveness of natural exposure to a rewarding experience to cure depressive symptoms is reminiscent of anhedonia (the inability to derive pleasure from activities usually found enjoyable). In summary, results from optogenetics support the therapeutic effectiveness of manipulative interventions into underlying neurocircuits for psychiatric disorders.
Optogenetic stimulation may be a new therapeutic option for clinical use in humans. An excellent example for the therapeutic potential of optogenetics has been provided by a mouse model of refractory epilepsy. In this model, the authors demonstrated that the expression and on-demand light activation of NpHR in hippocampal excitatory neurons successfully inhibited spontaneous seizures. 41 In the ophthalmologic field, ChR2 can substitute the phototransduction cascade and restore light sensitivity in mouse models of retinitis pigmentosa 42 (a group of hereditary diseases that lead to incurable blindness). However, the ethical concerns regarding benefits and unintended consequences of intervening in the brain are substantial. Therefore, the translation of optogenetics from basic research to clinical applications is challenging. Nonetheless, important progress is underway: The phase I/II trial for optogenetic retinitis pigmentosa treatment has been initiated. This treatment consists of ChR2 gene therapy administered as an injection into the eye. However, unlike in these neurological and ophthalmological disorders, the causal roles of specific neuronal circuits in psychiatric disorders remain to be elucidated. Therefore, the clinical application of optogenetics to treat psychiatric indications should be far more challenging. Realistically, additional basic research taking advantage of optogenetics is necessary to acquire more knowledge about these disorders. This includes the refinement of causal interventions, such as deep-brain stimulation (DBS) and transcranial magnetic stimulation (TMS). DBS and TMS have been applied to treat a variety of treatment-refractory psychiatric conditions. While the mechanisms of DBS have remained elusive and there are still several controversies about its action mechanism, its therapeutic success appears to stem from the modulation of neuronal activity that overwrites dysfunctional patterns of firing and replaces these patterns with less disturbing patterns. 43 An excellent example of such a result comes from cocaine addiction research. 44 Cocaine addiction is characterized by behavioral sensitization caused by cocaine-evoked potentiation of excitatory afferents onto dopamine D1-receptor-expressing (D1R) medium-sized spiny neurons in the nucleus accumbens. 45 Classical DBS protocols (highfrequency stimulation, >100 Hz) failed to alter cocaine-evoked plasticity and had only limited effects on behavioral sensitization. To ameliorate behavioral sensitization, cocaine-evoked synaptic potentiation would have to be reversed by a longterm depression (LTD) protocol. However, highfrequency stimulation protocols (>100 Hz) are unlikely to induce LTD. Therefore, the authors performed a detailed comparison between optogenetic and electrical stimulation. While ChR2 stimulation at 12 Hz induced robust LTD of excitatory transmission onto D1R medium-sized spiny neurons, an otherwise identical protocol using electrical stimulation did not. Based on previous studies showing that blockade of D1R is necessary for mGluR-dependent LTD, the authors examined whether the addition of D1R antagonists with electrical stimulation indeed elicited LTD. Neither 12-Hz DBS alone nor D1R antagonist administration alone affected sensitization. However, when administered in combination, sensitization was successfully abolished. In this way, the insight gained by optogenetics research helped define the proper stimulation protocol to ameliorate behavioral sensitization. The US Food and Drug Administration has approved DBS as a treatment for psychiatric disorders, such as obsessive-compulsive disorder, and its application is now extended in research to treat post-traumatic stress disorder, mood disorders, and schizophrenia. While DBS has proven effective for some patients, it potentially induces serious complications and side-effects. The investigation of appropriate stimulation protocols following an optogenetics-driven circuit-centric strategy could refine DBS protocols to restore normal transmission with long-lasting effects. Thus, optogenetics may represent a major advance for the treatment of psychiatric disorders.
CLOSING REMARKS
One of the inventors of optogenetics, Karl Deisseroth, was trained as a psychiatrist. Thus, it seems natural that his laboratory has made tremendous progresses in -and has accumulated invaluable findings for -psychiatric research using optogenetics. One of the goals of neuroscience research is to elucidate how specific neuronal populations form functional neuronal circuits and how these processes are altered in the disease state. The direct translation of optogenetic approaches to therapeutic interventions should be challenging in the psychiatric field. However, findings based on optogenetics will provide the knowledge necessary to establish circuit-centric therapeutics, overcoming the limitations of molecular-(and chemistry)-based drug designs.
